GlassScriptPhysician profile
Russell N Cecil
NPI 1750371308
$4,912.74
in general payments reported to CMS, 2019-2025
22 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $932 · 2021: $440 · 2022: $1,866 · 2023: $709 · 2024: $364 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prodigy Surgical Distribution, INC. | $2,226.17 | 2020-2024 | |
| Ferring Pharmaceuticals INC. | $863.20 | 2019-2025 | Euflexxa |
| Stryker Corporation | $414.95 | 2021-2025 | Gamma, T2, Variax |
| Depuy Synthes Sales INC. | $392.23 | 2019-2024 | Inhance, Attune, Trumatch |
| Amgen INC. | $196.53 | 2019-2024 | Krystexxa, Prolia, Evenity |
| Fidia Pharma USA INC. | $101.42 | 2019-2023 | Triluron, Hymovis |
| Dynasplint Systems INC. | $100.29 | 2022 | |
| Medacta USA, INC. | $88.46 | 2022-2023 | Primary Shoulder |
| Kowa Pharmaceuticals America, INC. | $77.51 | 2022-2023 | Seglentis |
| Treace Medical Concepts, INC. | $62.87 | 2023 | |
| Zimmer Biomet Holdings, INC. | $53.24 | 2022 | |
| Endo Pharmaceuticals INC. | $52.37 | 2019-2022 | |
| Smith+Nephew, INC. | $50.00 | 2023 | Or3o Dual Mobility, Redapt, R3 Acetabular |
| Bioventus LLC | $44.02 | 2019-2023 | Durolane |
| Novo Nordisk INC | $38.49 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $31.60 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $31.24 | 2024-2025 | |
| Horizon Therapeutics Plc | $22.62 | 2020 | |
| Relievant Medsystems, INC. | $21.86 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $15.88 | 2023 | Exparel, Zilretta, Iovera |
| Axogen | $14.98 | 2019 | |
| Convatec INC. | $12.81 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Cecil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.